FDA Warns Against Gadolinium Use In MRIs For Kidney Failure Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Contrast agent should be used in such patients only if “clearly necessary,” FDA says.
You may also be interested in...
FDA Contraindicates Three Gadolinium Imaging Agents In Severe Kidney Disease
However, the agency says all seven gadolinium-based contrast agents used in MRI and MRA procedures present a risk of nephrogenic systemic fibrosis.
FDA Contraindicates Three Gadolinium Imaging Agents In Severe Kidney Disease
However, the agency says all seven gadolinium-based contrast agents used in MRI and MRA procedures present a risk of nephrogenic systemic fibrosis.
Gadolinium Imaging Agents To Get Safety Review At FDA Advisory Committee
Sponsors are conducting mandatory clinical trials on the risk for patients with moderate to severe renal insufficiency.